University of Pittsburgh Epidemiology Data Center

Last updated

The Epidemiology Data Center (EDC) is recognized as an official University Center at the University of Pittsburgh; and is part of the Department of Epidemiology at the University of Pittsburgh Graduate School of Public Health. The EDC was formed in 1980 by Katherine M. Detre, M.D., Dr.P.H., [1] and is currently under the co-direction of Maria Mori Brooks, Ph.D., Steven H. Belle, Ph.D. and Stephen R. Wisniewski, Ph.D. [2]

Contents

Overview

The EDC has been involved in over 120 research projects sponsored by the National Institutes of Health and other agencies. Existing studies include a scientific assortment such as registries, case control studies, and clinical trials.

The center includes 70 full-time staff, 21 faculty, and 23 part-time and student employees. Faculty and staff cover a variety of educational backgrounds, and different fields of knowledge together with biostatisticians, applied mathematical statisticians, epidemiologists, physicians, programmers, data managers, systems analysts, data entry employees, and administrative personnel.

The EDC offers IT and network services for internal & external departments or organizations within the University district. Services include: Local Area Network, Server Administration, Software, Technical & Computer Support, VAX/VMS Time Sharing, Web/Media and Information Technology services. [3]

The Epidemiology Data Center is located at 4420 Bayard Street, Suite 600, Pittsburgh, PA 15260.

Current research

LITES – Linking Investigations in Trauma and Emergency Services: The Linking Investigations in Trauma and Emergency Services (LITES) is a research network of US trauma systems and centers with the capability to conduct prospective, multicenter, injury care and outcomes research of relevance to the Department of Defense (DOD). [4]

MINT – Myocardial Ischemia and Transfusion: MINT is a multicenter randomized clinical trial comparing red blood cell transfusion strategies for patients who have had a myocardial infarction and are anemic. The trial will enroll 3500 hospitalized patients diagnosed with myocardial infarction who are anemic (have blood counts less than 10 g/dL) to receive either a liberal or a restrictive transfusion strategy. [5]

PTC – Pulmonary Trials Cooperative: The Pulmonary Trials Cooperative brings together research protocol leaders, clinical centers, and research participants to develop new treatments and test existing clinical management strategies. [6]

Vit-D-Kids – Vitamin D Kids Asthma: This study will determine whether vitamin D3 helps to prevent severe asthma attacks in asthmatic children who are being treated with inhaled corticosteroids. Results from prior studies suggest that vitamin D reduces the risk of severe asthma attacks and that this protective effect may be due to immune modulation of viral illnesses or increased response to inhaled corticosteroids. [7]

SCD-CARRE – Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial: The Sickle Cell Disease and Cardiovascular Risk—Red Cell Exchange (SCD-CARRE) randomized clinical trial will enroll 150 adult participants with SCD in the United States and Europe. All participants will be followed on a monthly basis for one year. The SCD-CARRE trial is supported by a grant from the National Heart, Lung, and Blood Institute. [8]

BARI2D (Bypass Angioplasty Revascularization Investigation (BARI) 2 Diabetes: BARI2D’s program is to research whether or not patients with Type 2 Diabetes, if preliminary treatment with angioplasty or bypass surgical treatment is superior to preliminary treatment within a medical program. BARI2D includes comparison with two approaches to manage blood sugar: on condition that providing insulin stimulating meds or meds that sensitizes the body to on hand insulin [9]

Related Research Articles

<span class="mw-page-title-main">Anemia</span> Medical condition

Anemia or anaemia is a blood disorder in which the blood has a reduced ability to carry oxygen due to a lower than normal number of red blood cells, or a reduction in the amount of hemoglobin. The name is derived from Ancient Greek: ἀναιμία anaimia, meaning 'lack of blood', from ἀν- an-, 'not' and αἷμα haima, 'blood'. When anemia comes on slowly, the symptoms are often vague, such as tiredness, weakness, shortness of breath, headaches, and a reduced ability to exercise. When anemia is acute, symptoms may include confusion, feeling like one is going to pass out, loss of consciousness, and increased thirst. Anemia must be significant before a person becomes noticeably pale. Symptoms of anemia depend on how quickly hemoglobin decreases. Additional symptoms may occur depending on the underlying cause. Preoperative anemia can increase the risk of needing a blood transfusion following surgery. Anemia can be temporary or long term and can range from mild to severe.

A blood substitute is a substance used to mimic and fulfill some functions of biological blood. It aims to provide an alternative to blood transfusion, which is transferring blood or blood-based products from one person into another. Thus far, there are no well-accepted oxygen-carrying blood substitutes, which is the typical objective of a red blood cell transfusion; however, there are widely available non-blood volume expanders for cases where only volume restoration is required. These are helping doctors and surgeons avoid the risks of disease transmission and immune suppression, address the chronic blood donor shortage, and address the concerns of Jehovah's Witnesses and others who have religious objections to receiving transfused blood.

<span class="mw-page-title-main">Acute respiratory distress syndrome</span> Human disease

Acute respiratory distress syndrome (ARDS) is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. Symptoms include shortness of breath (dyspnea), rapid breathing (tachypnea), and bluish skin coloration (cyanosis). For those who survive, a decreased quality of life is common.

The National Heart, Lung, and Blood Institute (NHLBI) is the third largest Institute of the National Institutes of Health, located in Bethesda, Maryland, United States. It is tasked with allocating about $3.6 billion in FY 2020 in tax revenue to advancing the understanding of the following issues: development and progression of disease, diagnosis of disease, treatment of disease, disease prevention, reduction of health care disparities within the American population, and advancing the effectiveness of the US medical system. NHLBI's Director is Gary H. Gibbons (2012–present).

<span class="mw-page-title-main">Infarction</span> Tissue death due to inadequate blood supply

Infarction is tissue death (necrosis) due to inadequate blood supply to the affected area. It may be caused by artery blockages, rupture, mechanical compression, or vasoconstriction. The resulting lesion is referred to as an infarct (from the Latin infarctus, "stuffed into").

Intravascular ultrasound (IVUS) or intravascular echocardiography is a medical imaging methodology using a specially designed catheter with a miniaturized ultrasound probe attached to the distal end of the catheter. The proximal end of the catheter is attached to computerized ultrasound equipment. It allows the application of ultrasound technology, such as piezoelectric transducer or CMUT, to see from inside blood vessels out through the surrounding blood column, visualizing the endothelium of blood vessels.

<span class="mw-page-title-main">Watershed stroke</span> Medical condition

A watershed stroke is defined as a brain ischemia that is localized to the vulnerable border zones between the tissues supplied by the anterior, posterior and middle cerebral arteries. The actual blood stream blockage/restriction site can be located far away from the infarcts. Watershed locations are those border-zone regions in the brain supplied by the major cerebral arteries where blood supply is decreased. Watershed strokes are a concern because they comprise approximately 10% of all ischemic stroke cases. The watershed zones themselves are particularly susceptible to infarction from global ischemia as the distal nature of the vasculature predisposes these areas to be most sensitive to profound hypoperfusion.

Biopure Corporation was a biopharmaceutical company that specialized in oxygen therapeutics for both human and veterinary use. The company developed, manufactured, and marketed oxygen therapeutics, designed to transport oxygen to the body's tissues. The oxygen technology uses hemoglobin-based oxygen carrying molecules in solution (HBOCs) to increase oxygen transfer to the tissues. The competing companies with Biopure were Allied Pharmaceutical, Northfield Laboratories, Baxter International and Hemosol of Toronto. The company developed two products: Hemopure (HBOC-1) [hemoglobin glutamer-250 (bovine)] for human use, and Oxyglobin (HBOC-301) [hemoglobin glutamer-200 (bovine)] for veterinary use. As of April 2001, Hemopure was approved for commercial sale in South Africa for treatment of acute anemia in general surgery. However, Hemopure has not been able to gain approval in the U.K. or the U.S. because of safety and reliability concerns of the European Commission and the U.S. Food and Drug Administration (FDA) respectively. The company formed an agreement with the U.S. Navy to aid in preclinical testing of Hemopure for out-of-hospital treatment of trauma patients in hemorrhagic shock. Oxyglobin is the only oxygen therapeutic approved for treatment of canine anemia in both Europe and the U.S. and has been used in treatment for thousands of cases. Unable to obtain FDA approval for Hemopure to date, Biopure ceased operations in 2009 and its assets were purchased by OPK Biotech LLC in September 2009. On July 16, 2009 Biopure announced it had filed for bankruptcy protection under Chapter 11, Title 11, United States Code and entered into an agreement with OPK Biotech LLC for the sale of substantially all of its assets.

<span class="mw-page-title-main">Bivalirudin</span> Anticoagulant drug

Bivalirudin (Bivalitroban), sold under the brand names Angiomax and Angiox and manufactured by The Medicines Company, is a specific and reversible direct thrombin inhibitor (DTI).

An exchange transfusion is a blood transfusion in which the patient's blood or components of it are exchanged with other blood or blood products. The patient's blood is removed and replaced by donated blood or blood components. This exchange transfusion can be performed manually or using a machine (apheresis).

<span class="mw-page-title-main">Reviparin sodium</span> Pharmaceutical drug

Reviparin is an antithrombotic and belongs to the group of low molecular weight heparins (LMWH).

<span class="mw-page-title-main">Coronary stent</span> Medical apparatus implanted into coronary arteries

A coronary stent is a tube-shaped device placed in the coronary arteries that supply blood to the heart, to keep the arteries open in the treatment of coronary heart disease. It is used in a procedure called percutaneous coronary intervention (PCI). Coronary stents are now used in more than 90% of PCI procedures. Stents reduce angina and have been shown to improve survival and decrease adverse events in an acute myocardial infarction.

The acute chest syndrome is a vaso-occlusive crisis of the pulmonary vasculature commonly seen in people with sickle cell anemia. This condition commonly manifests with a new opacification of the lung(s) on a chest x-ray.

The following outline is provided as an overview of and topical guide to clinical research:

<span class="mw-page-title-main">Sickle cell disease</span> Group of genetic blood disorders

Sickle cell disease (SCD) is a group of blood disorders typically inherited. The most common type is known as sickle cell anaemia. It results in an abnormality in the oxygen-carrying protein haemoglobin found in red blood cells. This leads to a rigid, sickle-like shape under certain circumstances. Problems in sickle cell disease typically begin around 5 to 6 months of age. A number of health problems may develop, such as attacks of pain, anemia, swelling in the hands and feet, bacterial infections, and stroke. Long-term pain may develop as people get older. The average life expectancy in the developed world is 40 to 60 years.

Complications of diabetes mellitus include problems that develop rapidly (acute) or over time (chronic) and may affect many organ systems. The complications of diabetes can dramatically impair quality of life and cause long-lasting disability. Overall, complications are far less common and less severe in people with well-controlled blood sugar levels. Some non-modifiable risk factors such as age at diabetes onset, type of diabetes, gender and genetics may influence risk. Other health problems compound the chronic complications of diabetes such as smoking, obesity, high blood pressure, elevated cholesterol levels, and lack of regular exercise. Complications of diabetes are a strong risk factor for severe COVID-19 illness.

<span class="mw-page-title-main">Julie Makani</span> Tanzanian medical researcher

Julie Makani is a Tanzanian medical researcher. From 2014 she is Wellcome Trust Research Fellow and Associate Professor in the Department of Haematology and Blood Transfusion at the Muhimbili University of Health and Allied Sciences (MUHAS). Also a visiting fellow and consultant to the Nuffield Department of Medicine, University of Oxford, she is based in Dar es Salaam, Tanzania. In 2011, she received the Royal Society Pfizer Award for her work with sickle cell disease.

Remote ischemic conditioning (RIC) is an experimental medical procedure that aims to reduce the severity of ischaemic injury to an organ such as the heart or the brain, most commonly in the situation of a heart attack or a stroke, or during procedures such as heart surgery when the heart may temporary suffer ischaemia during the operation, by triggering the body's natural protection against tissue injury. Although noted to have some benefits in experimental models in animals, this is still an experimental procedure in humans and initial evidence from small studies have not been replicated in larger clinical trials. Successive clinical trials have failed to identify evidence supporting a protective role in humans.

<span class="mw-page-title-main">Stephanie J. Weinstein</span> American nutritionist and epidemiologist

Stephanie Joan Weinstein is an American nutritionist and cancer epidemiologist who is a staff scientist in the metabolic epidemiology branch at the National Cancer Institute. She researches diet and cancer associations with a with a focus on vitamin D, vitamin E, and one-carbon metabolism. Weinstein was formerly an environmental toxicologist at a consulting firm.

References

  1. The Lancet, Volume 367, Issue 9512, 4 March 2006-10 March 2006
  2. Epidemiology Data Center: Who We Are
  3. 2007 EDC Guide to Projects, Resources and IT Services
  4. "Pitt to Lead Trauma Network, up to $90M in Trauma Research".
  5. Md, Jeffrey L. Carson (10 March 2019). "Myocardial Ischemia and Transfusion Pilot".
  6. "RFA-HL-15-015: Multi-Site Clinical Trials for the Pulmonary Trials Cooperative (PTC) (U01)".
  7. Md, Juan Celedon (10 August 2021). "Vitamin D to Prevent Severe Asthma Exacerbations".
  8. Gladwin, Mark (20 July 2021). "Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)".
  9. Clinicaltrials.gov